Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Runcaciguat PK in Hepatic Impairment
NCT04820621Phase 1Terminated
- Sponsor
- Bayer
- Start
- Apr 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of runcaciguat in chronic kidney disease (CKD) (3 arms), sponsored by Bayer. Primary endpoints: Area under the concentration vs. time curve from zero to infinity, Unbound AUC and 2 more. Started Apr 2021; status: terminated.
02
Drugs
runcaciguat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04820621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04820621.